{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T17:23:00Z","timestamp":1793380980209,"version":"4.5.0"},"reference-count":150,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,3]],"date-time":"2024-12-03T00:00:00Z","timestamp":1733184000000},"content-version":"am","delay-in-days":398,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Blood Reviews"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1016\/j.blre.2023.101080","type":"journal-article","created":{"date-parts":[[2023,4,11]],"date-time":"2023-04-11T20:00:41Z","timestamp":1681243241000},"page":"101080","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":44,"special_numbering":"C","title":["Combining post-transplant cyclophosphamide with antithymocyte globulin for graft-versus-host disease prophylaxis in hematological malignancies"],"prefix":"10.1016","volume":"62","author":[{"given":"R\u00e9my","family":"Dul\u00e9ry","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eolia","family":"Brissot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamad","family":"Mohty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"22","key":"10.1016\/j.blre.2023.101080_bb0005","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1056\/NEJMra1609337","article-title":"Acute graft-versus-host disease - biologic process, prevention, and therapy","volume":"377","author":"Zeiser","year":"2017","journal-title":"N Engl J Med"},{"issue":"26","key":"10.1016\/j.blre.2023.101080_bb0010","article-title":"Pathophysiology of chronic graft-versus-host disease and therapeutic targets","volume":"377","author":"Zeiser","year":"2017","journal-title":"N Engl J Med [Internet]"},{"issue":"5","key":"10.1016\/j.blre.2023.101080_bb0015","doi-asserted-by":"crossref","first-page":"958","DOI":"10.3324\/haematol.2016.156356","article-title":"Improved survival after acute graft-versus-host disease diagnosis in the modern era","volume":"102","author":"Khoury","year":"2017","journal-title":"Haematologica."},{"issue":"10","key":"10.1016\/j.blre.2023.101080_bb0020","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1182\/blood-2017-01-761627","article-title":"How much immunosuppression do we need?","volume":"129","author":"Spyridonidis","year":"2017","journal-title":"Blood."},{"issue":"6","key":"10.1016\/j.blre.2023.101080_bb0025","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1038\/s41409-020-0792-x","article-title":"Rabbit ATG\/ATLG in preventing graft-versus-host disease after allogeneic stem cell transplantation: consensus-based recommendations by an international expert panel","volume":"55","author":"Bonifazi","year":"2020","journal-title":"Bone Marrow Transplant"},{"issue":"10","key":"10.1016\/j.blre.2023.101080_bb0030","article-title":"Antithymocyte globulin for graft-versus-host disease prophylaxis in transplants from unrelated donors: 2 randomized studies from Gruppo Italiano Trapianti Midollo Osseo (GITMO)","volume":"98","author":"Bacigalupo","year":"2001","journal-title":"Blood [Internet]"},{"issue":"9","key":"10.1016\/j.blre.2023.101080_bb0035","doi-asserted-by":"crossref","DOI":"10.1016\/S1470-2045(09)70225-6","article-title":"Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial","volume":"10","author":"Finke","year":"2009","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.blre.2023.101080_bb0040","article-title":"Antilymphocyte globulin for prevention of chronic graft-versus-host disease","volume":"374","author":"Kr\u00f6ger","year":"2016","journal-title":"N Engl J Med [Internet]"},{"issue":"2","key":"10.1016\/j.blre.2023.101080_bb0045","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/S1470-2045(15)00462-3","article-title":"Pretreatment with anti-thymocyte globulin versus no anti-thymocyte globulin in patients with haematological malignancies undergoing haemopoietic cell transplantation from unrelated donors: a randomised, controlled, open-label, phase 3, multicentre trial","volume":"17","author":"Walker","year":"2016","journal-title":"Lancet Oncol"},{"issue":"36","key":"10.1016\/j.blre.2023.101080_bb0050","doi-asserted-by":"crossref","first-page":"4003","DOI":"10.1200\/JCO.2017.75.8177","article-title":"Prospective, randomized, double-blind, phase III clinical trial of anti-T-lymphocyte globulin to assess impact on chronic graft-versus-host disease-free survival in patients undergoing HLA-matched unrelated Myeloablative hematopoietic cell transplantation","volume":"35","author":"Soiffer","year":"2017","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"29","key":"10.1016\/j.blre.2023.101080_bb0055","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.20.00150","article-title":"Antithymocyte globulin for matched sibling donor transplantation in patients with hematologic malignancies: a multicenter, open-label, randomized controlled study","volume":"38","author":"Chang","year":"2020","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"2","key":"10.1016\/j.blre.2023.101080_bb0060","doi-asserted-by":"crossref","first-page":"224","DOI":"10.3324\/haematol.2016.148510","article-title":"Anti-thymocyte globulin as graft-versus-host disease prevention in the setting of allogeneic peripheral blood stem cell transplantation: a review from the acute leukemia working Party of the European Society for blood and marrow transplantation","volume":"102","author":"Baron","year":"2017","journal-title":"Haematologica."},{"key":"10.1016\/j.blre.2023.101080_bb0065","article-title":"Haploidentical transplants with a G-CSF\/ATG-based protocol: experience from China","author":"Xu","year":"2022","journal-title":"Blood Rev"},{"issue":"6","key":"10.1016\/j.blre.2023.101080_bb0070","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/j.bbmt.2008.03.005","article-title":"HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide","volume":"14","author":"Luznik","year":"2008","journal-title":"Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant"},{"issue":"1","key":"10.1016\/j.blre.2023.101080_bb0075","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.bbmt.2015.11.001","article-title":"Haploidentical hematopoietic stem cell transplantation: a global overview comparing Asia, the European Union, and the United States","volume":"22","author":"Apperley","year":"2016","journal-title":"Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant"},{"issue":"2","key":"10.1016\/j.blre.2023.101080_bb0080","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1053\/j.seminhematol.2016.01.005","article-title":"Haploidentical bone marrow and stem cell transplantation: experience with post-transplantation cyclophosphamide","volume":"53","author":"Robinson","year":"2016","journal-title":"Semin Hematol"},{"key":"10.1016\/j.blre.2023.101080_bb0085","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.exphem.2017.11.001","article-title":"T-cell-replete haploidentical transplantation in acute myeloid leukemia","volume":"58","author":"Castagna","year":"2018","journal-title":"Exp Hematol"},{"issue":"2","key":"10.1016\/j.blre.2023.101080_bb0090","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1097\/MOH.0000000000000412","article-title":"Have haploidentical transplants replaced umbilical cord transplants for acute leukemias?","volume":"25","author":"Liu","year":"2018","journal-title":"Curr Opin Hematol"},{"issue":"9","key":"10.1016\/j.blre.2023.101080_bb0095","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1038\/s41409-018-0153-1","article-title":"Is the use of unrelated donor transplantation leveling off in Europe? The 2016 European Society for Blood and Marrow Transplant activity survey report","volume":"53","author":"Passweg","year":"2018","journal-title":"Bone Marrow Transplant"},{"issue":"10","key":"10.1016\/j.blre.2023.101080_bb0100","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1016\/j.bbmt.2014.05.029","article-title":"Unmanipulated haploidentical transplants compared with other alternative donors and matched sibling grafts","volume":"20","author":"Raiola","year":"2014","journal-title":"Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant"},{"issue":"8","key":"10.1016\/j.blre.2023.101080_bb0105","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1182\/blood-2015-04-639831","article-title":"Haploidentical transplant with posttransplant cyclophosphamide vs matched unrelated donor transplant for acute myeloid leukemia","volume":"126","author":"Ciurea","year":"2015","journal-title":"Blood."},{"issue":"1","key":"10.1016\/j.blre.2023.101080_bb0110","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.bbmt.2015.09.002","volume":"22","author":"Bashey","year":"2016","journal-title":"Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant"},{"issue":"4","key":"10.1016\/j.blre.2023.101080_bb0115","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1038\/s41409-017-0018-z","article-title":"Better outcome with haploidentical over HLA-matched related donors in patients with Hodgkin\u2019s lymphoma undergoing allogeneic haematopoietic cell transplantation-a study by the francophone Society of Bone Marrow Transplantation and Cellular Therapy","volume":"53","author":"Gauthier","year":"2018","journal-title":"Bone Marrow Transplant"},{"issue":"5","key":"10.1016\/j.blre.2023.101080_bb0120","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1016\/j.bbmt.2018.01.005","article-title":"Sequential conditioning with Thiotepa in T cell- replete hematopoietic stem cell transplantation for the treatment of refractory hematologic malignancies: comparison with matched related, Haplo-mismatched, and unrelated donorsBiol Blood Marrow","volume":"24","author":"Dul\u00e9ry","year":"2018","journal-title":"Transplant J Am Soc Blood Marrow Transplant"},{"issue":"2","key":"10.1016\/j.blre.2023.101080_bb0125","doi-asserted-by":"crossref","first-page":"49","DOI":"10.2991\/chi.d.200405.001","article-title":"Haploidentical hematopoietic stem cell transplantation followed by \u2018post-cyclophosphamide\u2019: the future of allogeneic stem cell transplant","volume":"2","author":"Cytryn","year":"2020","journal-title":"Clin Hematol Int"},{"key":"10.1016\/j.blre.2023.101080_bb0130","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtct.2022.07.006","article-title":"Comparison of outcomes after unrelated double-unit cord blood and haploidentical peripheral blood stem cell transplantation in adults with acute myeloid leukemia, a study on behalf of Eurocord and ALWP-EBMT","author":"Ruggeri","year":"2022","journal-title":"Transplant Cell Ther"},{"issue":"4","key":"10.1016\/j.blre.2023.101080_bb0135","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1200\/JCO.21.02293","article-title":"Randomized phase III BMT CTN trial of Calcineurin inhibitor-free chronic graft-versus-host disease interventions in Myeloablative hematopoietic cell transplantation for hematologic malignancies","volume":"40","author":"Luznik","year":"2022","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"2","key":"10.1016\/j.blre.2023.101080_bb0140","doi-asserted-by":"crossref","first-page":"86.e1","DOI":"10.1016\/j.jtct.2021.11.013","article-title":"Graft-versus-host disease prophylaxis with post-transplantation cyclophosphamide versus cyclosporine a and methotrexate in matched sibling donor transplantation","volume":"28","author":"Nagler","year":"2022","journal-title":"Transplant Cell Ther"},{"issue":"11","key":"10.1016\/j.blre.2023.101080_bb0145","doi-asserted-by":"crossref","first-page":"3378","DOI":"10.1182\/bloodadvances.2021005847","article-title":"Posttransplant cyclophosphamide for prevention of graft-versus-host disease: results of the prospective randomized HOVON-96 trial","volume":"6","author":"Broers","year":"2022","journal-title":"Blood Adv"},{"issue":"3","key":"10.1016\/j.blre.2023.101080_bb0150","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1200\/JCO.2000.18.3.537","article-title":"Randomized trial of bone marrow versus lenograstim-primed blood cell allogeneic transplantation in patients with early-stage leukemia: a report from the Soci\u00e9t\u00e9 Fran\u00e7aise de Greffe de Moelle","volume":"18","author":"Blaise","year":"2000","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"3","key":"10.1016\/j.blre.2023.101080_bb0155","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1056\/NEJM200101183440303","article-title":"Transplantation of bone marrow as compared with peripheral-blood cells from HLA-identical relatives in patients with hematologic cancers","volume":"344","author":"Bensinger","year":"2001","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.blre.2023.101080_bb0160","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1182\/blood-2002-01-0048","article-title":"A randomized multicenter comparison of bone marrow and peripheral blood in recipients of matched sibling allogeneic transplants for myeloid malignancies","volume":"100","author":"Couban","year":"2002","journal-title":"Blood."},{"issue":"3","key":"10.1016\/j.blre.2023.101080_bb0165","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1182\/blood-2001-12-0304","article-title":"Transplantation of mobilized peripheral blood cells to HLA-identical siblings with standard-risk leukemia","volume":"100","author":"Schmitz","year":"2002","journal-title":"Blood."},{"issue":"16","key":"10.1016\/j.blre.2023.101080_bb0170","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1056\/NEJMoa1203517","article-title":"Peripheral-blood stem cells versus bone marrow from unrelated donors","volume":"367","author":"Anasetti","year":"2012","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.blre.2023.101080_bb0175","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1016\/j.bbmt.2016.04.017","article-title":"Filgrastim-stimulated bone marrow compared with Filgrastim-mobilized peripheral blood in Myeloablative sibling Allografting for patients with hematologic malignancies: a randomized Canadian blood and marrow transplant group study","volume":"22","author":"Couban","year":"2016","journal-title":"Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant"},{"issue":"7","key":"10.1016\/j.blre.2023.101080_bb0180","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1038\/s41409-021-01227-8","article-title":"Hematopoietic cell transplantation and cellular therapy survey of the EBMT: monitoring of activities and trends over 30 years","volume":"56","author":"Passweg","year":"2021","journal-title":"Bone Marrow Transplant"},{"issue":"4","key":"10.1016\/j.blre.2023.101080_bb0185","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1182\/blood-2007-03-081596","article-title":"Worse outcome and more chronic GVHD with peripheral blood progenitor cells than bone marrow in HLA-matched sibling donor transplants for young patients with severe acquired aplastic anemia","volume":"110","author":"Schrezenmeier","year":"2007","journal-title":"Blood."},{"issue":"5","key":"10.1016\/j.blre.2023.101080_bb0190","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1016\/j.bbmt.2016.01.012","article-title":"Comparing outcomes with bone marrow or peripheral blood stem cells as graft source for matched sibling transplants in severe aplastic Anemia across different economic regions","volume":"22","author":"Kumar","year":"2016","journal-title":"Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant"},{"issue":"7","key":"10.1016\/j.blre.2023.101080_bb0195","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1002\/cncr.31228","article-title":"Bone marrow versus mobilized peripheral blood stem cells in haploidentical transplants using posttransplantation cyclophosphamide","volume":"124","author":"Ruggeri","year":"2018","journal-title":"Cancer."},{"issue":"12","key":"10.1016\/j.blre.2023.101080_bb0200","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1038\/bmt.2016.215","article-title":"Comparable outcomes with marrow or peripheral blood as stem cell sources for hematopoietic cell transplantation from haploidentical donors after non-ablative conditioning: a matched-pair analysis","volume":"51","author":"O\u2019Donnell","year":"2016","journal-title":"Bone Marrow Transplant"},{"issue":"26","key":"10.1016\/j.blre.2023.101080_bb0205","doi-asserted-by":"crossref","first-page":"3002","DOI":"10.1200\/JCO.2017.72.8428","article-title":"Mobilized peripheral blood stem cells versus unstimulated bone marrow as a graft source for T-cell-replete Haploidentical donor transplantation using post-transplant cyclophosphamide","volume":"35","author":"Bashey","year":"2017","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"12","key":"10.1016\/j.blre.2023.101080_bb0210","doi-asserted-by":"crossref","first-page":"1003.e1","DOI":"10.1016\/j.jtct.2021.09.003","article-title":"Bone marrow versus peripheral blood grafts for Haploidentical hematopoietic cell transplantation with post-transplantation cyclophosphamide","volume":"27","author":"Mehta","year":"2021","journal-title":"Transplant Cell Ther"},{"issue":"9","key":"10.1016\/j.blre.2023.101080_bb0215","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1016\/j.bbmt.2019.05.017","article-title":"Peripheral blood stem cells versus bone marrow for T cell-replete Haploidentical transplantation with post-transplant cyclophosphamide in Hodgkin lymphoma","volume":"25","author":"Mariotti","year":"2019","journal-title":"Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant"},{"issue":"10","key":"10.1016\/j.blre.2023.101080_bb0220","doi-asserted-by":"crossref","first-page":"2766","DOI":"10.1038\/s41375-020-0850-9","article-title":"Bone marrow versus mobilized peripheral blood stem cell graft in T-cell-replete haploidentical transplantation in acute lymphoblastic leukemia","volume":"34","author":"Nagler","year":"2020","journal-title":"Leukemia."},{"issue":"3","key":"10.1016\/j.blre.2023.101080_bb0225","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1158\/1078-0432.CCR-20-2809","article-title":"Comparison of Haploidentical bone marrow versus matched unrelated donor peripheral blood stem cell transplantation with Posttransplant cyclophosphamide in patients with acute leukemia","volume":"27","author":"Nagler","year":"2021","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"issue":"8","key":"10.1016\/j.blre.2023.101080_bb0230","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1016\/j.bbmt.2020.05.001","article-title":"Risk factors for graft-versus-host disease in Haploidentical hematopoietic cell transplantation using post-transplant cyclophosphamide","volume":"26","author":"Im","year":"2020","journal-title":"Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant"},{"issue":"6","key":"10.1016\/j.blre.2023.101080_bb0235","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/j.bbmt.2014.11.676","article-title":"Rabbit anti-T cell globulin in allogeneic hematopoietic cell transplantation","volume":"21","author":"Storek","year":"2015","journal-title":"Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant"},{"issue":"2","key":"10.1016\/j.blre.2023.101080_bb0240","doi-asserted-by":"crossref","first-page":"224","DOI":"10.3324\/haematol.2016.148510","article-title":"Anti-thymocyte globulin as graft-versus-host disease prevention in the setting of allogeneic peripheral blood stem cell transplantation: a review from the acute leukemia working Party of the European Society for blood and marrow transplantation","volume":"102","author":"Baron","year":"2017","journal-title":"Haematologica."},{"issue":"7","key":"10.1016\/j.blre.2023.101080_bb0245","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1038\/sj.leu.2404683","article-title":"Mechanisms of action of antithymocyte globulin: T-cell depletion and beyond","volume":"21","author":"Mohty","year":"2007","journal-title":"Leukemia."},{"issue":"12","key":"10.1016\/j.blre.2023.101080_bb0250","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1016\/j.bbmt.2012.07.004","article-title":"Different outcomes between cyclophosphamide plus horse or rabbit antithymocyte globulin for HLA-identical sibling bone marrow transplant in severe aplastic anemia","volume":"18","author":"Atta","year":"2012","journal-title":"Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant"},{"issue":"1","key":"10.1016\/j.blre.2023.101080_bb0255","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.bbmt.2017.08.029","article-title":"Optimizing antithymocyte globulin dosing for unrelated donor allogeneic hematopoietic cell transplantation based on recipient absolute lymphocyte count","volume":"24","author":"Kennedy","year":"2018","journal-title":"Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant"},{"issue":"3","key":"10.1016\/j.blre.2023.101080_bb0260","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1038\/s41409-019-0643-9","article-title":"Personalizing rabbit anti-thymocyte globulin therapy for prevention of graft-versus-host disease after allogeneic hematopoietic cell transplantation: is there an optimal dose?","volume":"55","author":"Shichijo","year":"2020","journal-title":"Bone Marrow Transplant"},{"issue":"5","key":"10.1016\/j.blre.2023.101080_bb0265","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1002\/cncr.27858","article-title":"Two days of antithymocyte globulin are associated with a reduced incidence of acute and chronic graft-versus-host disease in reduced-intensity conditioning transplantation for hematologic diseases","volume":"119","author":"Crocchiolo","year":"2013","journal-title":"Cancer."},{"issue":"5","key":"10.1016\/j.blre.2023.101080_bb0270","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1038\/bmt.2012.3","article-title":"The increase from 2.5 to 5 mg\/kg of rabbit anti-thymocyte-globulin dose in reduced intensity conditioning reduces acute and chronic GVHD for patients with myeloid malignancies undergoing Allo-SCT","volume":"47","author":"Devillier","year":"2012","journal-title":"Bone Marrow Transplant"},{"issue":"3","key":"10.1016\/j.blre.2023.101080_bb0275","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1038\/bmt.2013.204","volume":"49","author":"Baron","year":"2014","journal-title":"Bone Marrow Transplant"},{"issue":"13","key":"10.1016\/j.blre.2023.101080_bb0280","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1056\/NEJM198509263131301","article-title":"Marrow transplantation from related donors other than HLA-identical siblings","volume":"313","author":"Beatty","year":"1985","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.blre.2023.101080_bb0285","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1056\/NEJM198901263200401","article-title":"Effect of HLA compatibility on engraftment of bone marrow transplants in patients with leukemia or lymphoma","volume":"320","author":"Anasetti","year":"1989","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.blre.2023.101080_bb0290","first-page":"229","article-title":"A novel approach to HLA-mismatched transplantation","volume":"36","author":"Huang","year":"2004","journal-title":"Beijing Da Xue Xue Bao"},{"issue":"5","key":"10.1016\/j.blre.2023.101080_bb0295","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1084\/jem.125.5.833","article-title":"Studies on cyclophosphamide-induced tolerance to sheep erythrocytes","volume":"125","author":"Aisenberg","year":"1967","journal-title":"J Exp Med"},{"issue":"7715","key":"10.1016\/j.blre.2023.101080_bb0300","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/S0140-6736(71)92046-0","article-title":"Cyclophosphamide and human organ transplantation","volume":"2","author":"Starzl","year":"1971","journal-title":"Lancet Lond Engl"},{"issue":"2","key":"10.1016\/j.blre.2023.101080_bb0305","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1182\/blood.V41.2.273.273","article-title":"Mechanisms of immunosuppression: effects of cyclophosphamide on cellular immunity","volume":"41","author":"Winkelstein","year":"1973","journal-title":"Blood."},{"issue":"6","key":"10.1016\/j.blre.2023.101080_bb0310","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1097\/00007890-198406000-00011","article-title":"Drug-induced tolerance to allografts in mice. I. Difference between tumor and skin grafts","volume":"37","author":"Shin","year":"1984","journal-title":"Transplantation."},{"issue":"2","key":"10.1016\/j.blre.2023.101080_bb0315","first-page":"363","article-title":"Drug-induced tolerance to allografts in mice. VII. Optimal protocol and mechanism of cyclophosphamide-induced tolerance in an H-2 haplotype-identical strain combination","volume":"18","author":"Mayumi","year":"1986","journal-title":"Transplant Proc"},{"issue":"4","key":"10.1016\/j.blre.2023.101080_bb0320","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1097\/00007890-198610000-00018","article-title":"Drug-induced tolerance to allografts in mice. IX. Establishment of complete chimerism by allogeneic spleen cell transplantation from donors made tolerant to H-2-identical recipients","volume":"42","author":"Mayumi","year":"1986","journal-title":"Transplantation."},{"issue":"2","key":"10.1016\/j.blre.2023.101080_bb0325","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.bbmt.2019.09.030","article-title":"Optimized timing of post-transplantation cyclophosphamide in MHC-Haploidentical murine hematopoietic cell transplantation","volume":"26","author":"Wachsmuth","year":"2020","journal-title":"Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant"},{"issue":"9","key":"10.1016\/j.blre.2023.101080_bb0330","first-page":"4179","article-title":"A nonlethal conditioning approach to achieve durable multilineage mixed chimerism and tolerance across major, minor, and hematopoietic histocompatibility barriers","volume":"155","author":"Colson","year":"1995","journal-title":"J Immunol Baltim Md 1950"},{"issue":"5","key":"10.1016\/j.blre.2023.101080_bb0335","first-page":"1303","article-title":"Sequential mechanisms of cyclophosphamide-induced skin allograft tolerance including the intrathymic clonal deletion followed by late breakdown of the clonal deletion","volume":"145","author":"Eto","year":"1990","journal-title":"J Immunol Baltim Md 1950"},{"issue":"5","key":"10.1016\/j.blre.2023.101080_bb0340","first-page":"1402","article-title":"Specific destruction of host-reactive mature T cells of donor origin prevents graft-versus-host disease in cyclophosphamide-induced tolerant mice","volume":"146","author":"Eto","year":"1991","journal-title":"J Immunol Baltim Md 1950"},{"issue":"8","key":"10.1016\/j.blre.2023.101080_bb0345","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1016\/0145-2126(85)90072-4","article-title":"4-Hydroperoxycyclophosphamide inhibits proliferation by human granulocyte-macrophage colony-forming cells (GM-CFC) but spares more primitive progenitor cells","volume":"9","author":"Gordon","year":"1985","journal-title":"Leuk Res"},{"issue":"4","key":"10.1016\/j.blre.2023.101080_bb0350","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1007\/s00280-001-0412-4","volume":"49","author":"Sl\u00e1dek","year":"2002","journal-title":"Cancer Chemother Pharmacol"},{"issue":"12","key":"10.1016\/j.blre.2023.101080_bb0355","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1016\/j.bbmt.2012.09.005","article-title":"Haploidentical transplantation: repurposing cyclophosphamide","volume":"18","author":"Jones","year":"2012","journal-title":"Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant"},{"issue":"211","key":"10.1016\/j.blre.2023.101080_bb0360","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3006960","article-title":"Aldehyde dehydrogenase expression drives human regulatory T cell resistance to posttransplantation cyclophosphamide","volume":"5","author":"Kanakry","year":"2013","journal-title":"Sci Transl Med"},{"issue":"13","key":"10.1016\/j.blre.2023.101080_bb0365","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1182\/blood-2013-10-525873","article-title":"Donor CD4+ Foxp3+ regulatory T cells are necessary for posttransplantation cyclophosphamide-mediated protection against GVHD in mice","volume":"124","author":"Ganguly","year":"2014","journal-title":"Blood."},{"issue":"4","key":"10.1016\/j.blre.2023.101080_bb0370","doi-asserted-by":"crossref","first-page":"203.e1","DOI":"10.1016\/j.jtct.2021.12.019","article-title":"Early recovery of myeloid-derived suppressor cells after allogeneic hematopoietic transplant: comparison of post-transplantation cyclophosphamide to standard graft-versus-host disease prophylaxis","volume":"28","author":"Oshrine","year":"2022","journal-title":"Transplant Cell Ther"},{"issue":"Suppl. 2","key":"10.1016\/j.blre.2023.101080_bb0375","article-title":"Nonmyeloablative, HLA-haploidentical bone marrow transplantation with high dose, post-transplantation cyclophosphamide","volume":"3","author":"Munchel","year":"2011","journal-title":"Pediatr Rep"},{"issue":"2","key":"10.1016\/j.blre.2023.101080_bb0380","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1182\/blood-2011-03-344853","article-title":"Alternative donor transplantation after reduced intensity conditioning: results of parallel phase 2 trials using partially HLA-mismatched related bone marrow or unrelated double umbilical cord blood grafts","volume":"118","author":"Brunstein","year":"2011","journal-title":"Blood."},{"issue":"19","key":"10.1016\/j.blre.2023.101080_bb0385","doi-asserted-by":"crossref","first-page":"3024","DOI":"10.1182\/blood-2015-01-623991","article-title":"Risk-stratified outcomes of nonmyeloablative HLA-haploidentical BMT with high-dose posttransplantation cyclophosphamide","volume":"125","author":"McCurdy","year":"2015","journal-title":"Blood."},{"issue":"26","key":"10.1016\/j.blre.2023.101080_bb0390","doi-asserted-by":"crossref","first-page":"3141","DOI":"10.1200\/JCO.2015.66.3476","article-title":"Reduced-intensity transplantation for lymphomas using Haploidentical related donors versus HLA-matched sibling donors: a Center for International Blood and Marrow Transplant Research Analysis","volume":"34","author":"Ghosh","year":"2016","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"12","key":"10.1016\/j.blre.2023.101080_bb0395","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1016\/j.bbmt.2012.06.019","volume":"18","author":"Solomon","year":"2012","journal-title":"Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant"},{"issue":"10","key":"10.1016\/j.blre.2023.101080_bb0400","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1200\/JCO.2012.44.3523","article-title":"T-cell-replete HLA-haploidentical hematopoietic transplantation for hematologic malignancies using post-transplantation cyclophosphamide results in outcomes equivalent to those of contemporaneous HLA-matched related and unrelated donor transplantation","volume":"31","author":"Bashey","year":"2013","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"1","key":"10.1016\/j.blre.2023.101080_bb0405","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.bbmt.2012.08.014","article-title":"Unmanipulated Haploidentical bone marrow transplantation and Posttransplantation cyclophosphamide for hematologic malignancies after Myeloablative conditioning","volume":"19","author":"Raiola","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"issue":"8","key":"10.1016\/j.blre.2023.101080_bb0410","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1016\/j.bbmt.2015.04.025","article-title":"Post-transplantation cyclophosphamide and Sirolimus after Haploidentical hematopoietic stem cell transplantation using a Treosulfan-based Myeloablative conditioning and peripheral blood stem cells","volume":"21","author":"Cieri","year":"2015","journal-title":"Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant"},{"issue":"6","key":"10.1016\/j.blre.2023.101080_bb0415","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1016\/j.bbmt.2017.09.005","article-title":"Haploidentical transplantation for older patients with acute myeloid leukemia and myelodysplastic syndrome","volume":"24","author":"Ciurea","year":"2018","journal-title":"Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant"},{"issue":"1","key":"10.1016\/j.blre.2023.101080_bb0420","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1186\/s13045-017-0480-5","article-title":"Unmanipulated haploidentical stem cell transplantation in adults with acute lymphoblastic leukemia: a study on behalf of the acute leukemia working party of the EBMT","volume":"10","author":"Santoro","year":"2017","journal-title":"J Hematol OncolJ Hematol Oncol"},{"issue":"5","key":"10.1016\/j.blre.2023.101080_bb0425","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1016\/j.bbmt.2018.01.005","article-title":"Sequential conditioning with Thiotepa in T cell- replete hematopoietic stem cell transplantation for the treatment of refractory hematologic malignancies: comparison with matched related, Haplo-mismatched, and unrelated donors","volume":"24","author":"Dul\u00e9ry","year":"2018","journal-title":"Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant"},{"issue":"7","key":"10.1016\/j.blre.2023.101080_bb0430","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1016\/j.bbmt.2019.02.025","article-title":"Busulfan, and Fludarabine conditioning regimen in T cell-replete HLA-Haploidentical hematopoietic stem cell transplantation","volume":"25","author":"Dul\u00e9ry","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"issue":"4","key":"10.1016\/j.blre.2023.101080_bb0435","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1038\/s41409-019-0726-7","article-title":"Thiotepa and antithymocyte globulin-based conditioning prior to haploidentical transplantation with posttransplant cyclophosphamide in high-risk hematological malignancies","volume":"55","author":"Peric","year":"2020","journal-title":"Bone Marrow Transplant"},{"issue":"1","key":"10.1016\/j.blre.2023.101080_bb0440","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1038\/s41375-019-0544-3","article-title":"Haploidentical vs. unrelated allogeneic stem cell transplantation for acute lymphoblastic leukemia in first complete remission: on behalf of the ALWP of the EBMT","volume":"34","author":"Shem-Tov","year":"2020","journal-title":"Leukemia."},{"issue":"2","key":"10.1016\/j.blre.2023.101080_bb0445","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1080\/10428194.2020.1827246","article-title":"Thiotepa-busulfan-fludarabine as a conditioning regimen for patients with myelofibrosis undergoing allogeneic hematopoietic transplantation: a single center experience","volume":"62","author":"Memoli","year":"2021","journal-title":"Leuk Lymphoma"},{"issue":"9","key":"10.1016\/j.blre.2023.101080_bb0450","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1038\/s41409-022-01674-x","article-title":"Reduced intensity versus non-myeloablative conditioning regimen for haploidentical transplantation and post-transplantation cyclophosphamide in complete remission acute myeloid leukemia: a study from the ALWP of the EBMT","volume":"57","author":"Devillier","year":"2022","journal-title":"Bone Marrow Transplant"},{"issue":"10","key":"10.1016\/j.blre.2023.101080_bb0455","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1016\/j.bbmt.2016.06.010","article-title":"Severe cytokine-release syndrome after T cell-replete peripheral blood Haploidentical donor transplantation is associated with poor survival and anti-IL-6 therapy is safe and well tolerated","volume":"22","author":"Abboud","year":"2016","journal-title":"Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant"},{"issue":"11","key":"10.1016\/j.blre.2023.101080_bb0460","doi-asserted-by":"crossref","first-page":"2763","DOI":"10.1038\/s41409-021-01403-w","article-title":"Cytokine release syndrome after haploidentical hematopoietic cell transplantation: an international multicenter analysis","volume":"56","author":"Abboud","year":"2021","journal-title":"Bone Marrow Transplant"},{"issue":"12","key":"10.1016\/j.blre.2023.101080_bb0465","doi-asserted-by":"crossref","first-page":"2431","DOI":"10.1016\/j.bbmt.2019.07.027","article-title":"Severe cytokine release syndrome after Haploidentical peripheral blood stem cell transplantation","volume":"25","author":"Imus","year":"2019","journal-title":"Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant"},{"issue":"1","key":"10.1016\/j.blre.2023.101080_bb0470","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1002\/cam4.2607","article-title":"Pretransplant active disease status and HLA class II mismatching are associated with increased incidence and severity of cytokine release syndrome after haploidentical transplantation with posttransplant cyclophosphamide","volume":"9","author":"Mariotti","year":"2020","journal-title":"Cancer Med"},{"issue":"9","key":"10.1016\/j.blre.2023.101080_bb0475","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1016\/j.bbmt.2020.06.006","article-title":"Severity of cytokine release syndrome and its association with infections after T cell-replete Haploidentical related donor transplantation","volume":"26","author":"Abid","year":"2020","journal-title":"Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant"},{"issue":"2","key":"10.1016\/j.blre.2023.101080_bb0480","doi-asserted-by":"crossref","first-page":"111.e1","DOI":"10.1016\/j.jtct.2021.11.012","article-title":"Cytokine release syndrome following peripheral blood stem cell Haploidentical hematopoietic cell transplantation with post-transplantation cyclophosphamide","volume":"28","author":"Otoukesh","year":"2022","journal-title":"Transplant Cell Ther"},{"issue":"8","key":"10.1016\/j.blre.2023.101080_bb0485","doi-asserted-by":"crossref","first-page":"1982","DOI":"10.1080\/10428194.2021.1891231","article-title":"Grade 3-4 cytokine release syndrome is associated with poor survival in haploidentical peripheral blood stem cell transplantation","volume":"62","author":"Modi","year":"2021","journal-title":"Leuk Lymphoma"},{"issue":"9","key":"10.1016\/j.blre.2023.101080_bb0490","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1038\/leu.2015.98","article-title":"Comparison of outcomes after unrelated cord blood and unmanipulated haploidentical stem cell transplantation in adults with acute leukemia","volume":"29","author":"Ruggeri","year":"2015","journal-title":"Leukemia."},{"issue":"30","key":"10.1016\/j.blre.2023.101080_bb0495","doi-asserted-by":"crossref","first-page":"3425","DOI":"10.1200\/JCO.2017.72.6869","volume":"35","author":"Mart\u00ednez","year":"2017","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"11","key":"10.1016\/j.blre.2023.101080_bb0500","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1182\/blood-2015-10-672071","article-title":"Posttransplantation cyclophosphamide for prevention of graft-versus-host disease after HLA-matched mobilized blood cell transplantation","volume":"127","author":"Mielcarek","year":"2016","journal-title":"Blood."},{"issue":"3","key":"10.1016\/j.blre.2023.101080_bb0505","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.bbmt.2016.12.636","article-title":"Post-transplant cyclophosphamide and tacrolimus-mycophenolate Mofetil combination prevents graft-versus-host disease in allogeneic peripheral blood hematopoietic cell transplantation from HLA-matched donors","volume":"23","author":"Carnevale-Schianca","year":"2017","journal-title":"Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant"},{"issue":"11","key":"10.1016\/j.blre.2023.101080_bb0510","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1182\/blood-2016-06-723205","article-title":"Posttransplantation cyclophosphamide and sirolimus for prevention of GVHD after HLA-matched PBSC transplantation","volume":"128","author":"Greco","year":"2016","journal-title":"Blood."},{"issue":"1","key":"10.1016\/j.blre.2023.101080_bb0515","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/s13045-018-0586-4","article-title":"Post-transplant cyclophosphamide for graft-versus-host disease prophylaxis in HLA matched sibling or matched unrelated donor transplant for patients with acute leukemia, on behalf of ALWP-EBMT","volume":"11","author":"Ruggeri","year":"2018","journal-title":"J Hematol OncolJ Hematol Oncol"},{"issue":"3","key":"10.1016\/j.blre.2023.101080_bb0520","doi-asserted-by":"crossref","first-page":"e132","DOI":"10.1016\/S2352-3026(18)30221-7","volume":"6","author":"Bola\u00f1os-Meade","year":"2019","journal-title":"Lancet Haematol"},{"issue":"11","key":"10.1016\/j.blre.2023.101080_bb0525","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1182\/blood.2019000487","article-title":"Posttransplant cyclophosphamide vs antithymocyte globulin in HLA-mismatched unrelated donor transplantation","volume":"134","author":"Battipaglia","year":"2019","journal-title":"Blood."},{"issue":"1","key":"10.1016\/j.blre.2023.101080_bb0530","doi-asserted-by":"crossref","first-page":"5","DOI":"10.2991\/chi.d.200115.001","article-title":"Current status and future directions in graft-versus-host disease prevention following allogeneic blood and marrow transplantation in adults","volume":"2","author":"Tegla","year":"2020","journal-title":"Clin Hematol Int"},{"issue":"1","key":"10.1016\/j.blre.2023.101080_bb0535","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1186\/s13045-020-00923-0","article-title":"Post-transplant cyclophosphamide versus antithymocyte globulin in patients with acute myeloid leukemia in first complete remission undergoing allogeneic stem cell transplantation from 10\/10 HLA-matched unrelated donors","volume":"13","author":"Brissot","year":"2020","journal-title":"J Hematol OncolJ Hematol Oncol"},{"key":"10.1016\/j.blre.2023.101080_bb0540","doi-asserted-by":"crossref","first-page":"636","DOI":"10.3389\/fimmu.2020.00636","article-title":"Post-transplantation cyclophosphamide: from HLA-Haploidentical to matched-related and matched-unrelated donor blood and marrow transplantation","volume":"11","author":"Williams","year":"2020","journal-title":"Front Immunol"},{"issue":"2","key":"10.1016\/j.blre.2023.101080_bb0545","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1038\/s41375-020-0863-4","article-title":"Post-transplantation cyclophosphamide GvHD prophylaxis after hematopoietic stem cell transplantation from 9\/10 or 10\/10 HLA-matched unrelated donors for acute leukemia","volume":"35","author":"Lorentino","year":"2021","journal-title":"Leukemia."},{"issue":"2","key":"10.1016\/j.blre.2023.101080_bb0550","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1002\/cncr.33255","volume":"127","author":"Battipaglia","year":"2021","journal-title":"Cancer."},{"issue":"3","key":"10.1016\/j.blre.2023.101080_bb0555","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1182\/blood.2021011281","article-title":"HLA-haploidentical vs matched unrelated donor transplants with posttransplant cyclophosphamide-based prophylaxis","volume":"138","author":"Gooptu","year":"2021","journal-title":"Blood."},{"issue":"18","key":"10.1016\/j.blre.2023.101080_bb0560","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1200\/JCO.20.03502","article-title":"National Marrow Donor Program-Sponsored Multicenter, phase II trial of HLA-mismatched unrelated donor bone marrow transplantation using post-transplant cyclophosphamide","volume":"39","author":"Shaw","year":"2021","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"7","key":"10.1016\/j.blre.2023.101080_bb0565","doi-asserted-by":"crossref","first-page":"619.e1","DOI":"10.1016\/j.jtct.2021.03.022","article-title":"High-dose cyclophosphamide and tacrolimus as graft-versus-host disease prophylaxis for matched and mismatched unrelated donor transplantation","volume":"27","author":"Pedraza","year":"2021","journal-title":"Transplant Cell Ther"},{"issue":"5","key":"10.1016\/j.blre.2023.101080_bb0570","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1016\/j.bbmt.2018.01.011","article-title":"Shortened-duration tacrolimus after Nonmyeloablative, HLA-Haploidentical bone marrow transplantation","volume":"24","author":"Kasamon","year":"2018","journal-title":"Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant"},{"issue":"Suppl. 2","key":"10.1016\/j.blre.2023.101080_bb0575","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1038\/s41409-019-0594-1","article-title":"Graft versus host disease in unmanipulated haploidentical marrow transplantation with a modified post-transplant cyclophosphamide (PT-CY) regimen: an update on 425 patients","volume":"54","author":"Bacigalupo","year":"2019","journal-title":"Bone Marrow Transplant"},{"issue":"10","key":"10.1016\/j.blre.2023.101080_bb0580","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1016\/j.bbmt.2020.06.026","article-title":"Timing of post-transplantation cyclophosphamide Administration in Haploidentical Transplantation: a comparative study on behalf of the acute leukemia working Party of the European Society for blood and marrow transplantation","volume":"26","author":"Ruggeri","year":"2020","journal-title":"Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant"},{"issue":"10","key":"10.1016\/j.blre.2023.101080_bb0585","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/j.jtct.2022.07.013","article-title":"Characteristics of graft-versus-host disease (GvHD) after post-transplantation cyclophosphamide versus conventional GvHD prophylaxis","volume":"28","author":"Saliba","year":"2022","journal-title":"Transplant Cell Ther"},{"issue":"2","key":"10.1016\/j.blre.2023.101080_bb0590","first-page":"105","article-title":"Safety and efficacy of Haploidentical peripheral blood stem cell transplantation for myeloid malignancies using post-transplantation cyclophosphamide and anti-thymocyte globulin as graft-versus-host disease prophylaxis","volume":"1","author":"Salas","year":"2019","journal-title":"Clin Hematol Int"},{"issue":"5","key":"10.1016\/j.blre.2023.101080_bb0595","doi-asserted-by":"crossref","first-page":"428.e1","DOI":"10.1016\/j.jtct.2021.02.007","article-title":"Experience using anti-Thymocyte globulin with post-transplantation cyclophosphamide for graft-versus-host disease prophylaxis in peripheral blood Haploidentical stem cell transplantation","volume":"27","author":"Salas","year":"2021","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.blre.2023.101080_bb0600","doi-asserted-by":"crossref","DOI":"10.1177\/09636897221079739","article-title":"Lower absolute lymphocyte count before conditioning predicts high relapse risk in patients after Haploidentical peripheral blood stem cell transplantation with low dose anti-Thymocyte globulin\/post-transplant cyclophosphamide for GvHD prophylaxis","volume":"31","author":"Zhou","year":"2022","journal-title":"Cell Transplant"},{"key":"10.1016\/j.blre.2023.101080_bb0605","doi-asserted-by":"crossref","DOI":"10.1016\/j.leukres.2022.106918","volume":"120","author":"Barkhordar","year":"2022","journal-title":"Leuk Res"},{"issue":"9","key":"10.1016\/j.blre.2023.101080_bb0610","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/j.clml.2020.04.003","article-title":"Impact of adding antithymocyte globulin to Posttransplantation cyclophosphamide in Haploidentical stem-cell transplantation","volume":"20","author":"El-Cheikh","year":"2020","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"5","key":"10.1016\/j.blre.2023.101080_bb0615","first-page":"1441","article-title":"Posttransplant cyclophosphamide and antithymocyte globulin versus Posttransplant cyclophosphamide as graft-versus-host disease prophylaxis for peripheral blood stem cell Haploidentical transplants: comparison of T cell and NK effector reconstitution","volume":"205","author":"Makanga","year":"2020","journal-title":"J Immunol Baltim Md 1950"},{"issue":"4","key":"10.1016\/j.blre.2023.101080_bb0620","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.3390\/jcm11041106","article-title":"Addition of a single low dose of anti T-lymphocyte globulin to post-transplant cyclophosphamide after allogeneic hematopoietic stem cell transplant: a pilot study","volume":"11","author":"Xue","year":"2022","journal-title":"J Clin Med"},{"issue":"4","key":"10.1016\/j.blre.2023.101080_bb0625","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1038\/s41409-022-01908-y","article-title":"Reduced post-transplant cyclophosphamide doses in haploidentical hematopoietic cell transplantation for elderly patients with hematological malignancies","volume":"58","author":"Dul\u00e9ry","year":"2023","journal-title":"Bone Marrow Transplant"},{"issue":"9","key":"10.1016\/j.blre.2023.101080_bb0630","doi-asserted-by":"crossref","first-page":"587.e1","DOI":"10.1016\/j.jtct.2022.06.006","volume":"28","author":"Battipaglia","year":"2022","journal-title":"Transplant Cell Ther"},{"issue":"1","key":"10.1016\/j.blre.2023.101080_bb0635","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1186\/s13045-019-0781-y","article-title":"Low-dose post-transplant cyclophosphamide and anti-thymocyte globulin as an effective strategy for GVHD prevention in haploidentical patients","volume":"12","author":"Wang","year":"2019","journal-title":"J Hematol OncolJ Hematol Oncol"},{"issue":"3","key":"10.1016\/j.blre.2023.101080_bb0640","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1038\/s41409-020-01047-2","volume":"56","author":"Xu","year":"2021","journal-title":"Bone Marrow Transplant"},{"issue":"2","key":"10.1016\/j.blre.2023.101080_bb0645","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1111\/bjh.18483","volume":"200","author":"Zhang","year":"2023","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2023.101080_bb0650","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.921293","article-title":"Modified combination of anti-thymocyte globulin (ATG) and post-transplant cyclophosphamide (PTCy) as compared with standard ATG protocol in haploidentical peripheral blood stem cell transplantation for acute leukemia","volume":"13","author":"Barkhordar","year":"2022","journal-title":"Front Immunol"},{"issue":"1","key":"10.1016\/j.blre.2023.101080_bb0655","volume":"71","author":"Cao","year":"2023","journal-title":"Curr Res Transl Med"},{"issue":"4","key":"10.1016\/j.blre.2023.101080_bb0660","doi-asserted-by":"crossref","first-page":"857","DOI":"10.3324\/haematol.2020.271445","article-title":"Comparison of immune reconstitution between anti-T-lymphocyte globulin and posttransplant cyclophosphamide as acute graft-versus-host disease prophylaxis in allogeneic myeloablative peripheral blood stem cell transplantation","volume":"107","author":"Massoud","year":"2022","journal-title":"Haematologica."},{"issue":"9","key":"10.1016\/j.blre.2023.101080_bb0665","doi-asserted-by":"crossref","DOI":"10.1002\/cti2.1171","article-title":"High-dose post-transplant cyclophosphamide impairs \u03b3\u03b4 T-cell reconstitution after haploidentical haematopoietic stem cell transplantation using low-dose antithymocyte globulin and peripheral blood stem cell graft","volume":"9","author":"Stocker","year":"2020","journal-title":"Clin Transl Immunol"},{"issue":"12","key":"10.1016\/j.blre.2023.101080_bb0670","doi-asserted-by":"crossref","first-page":"e387","DOI":"10.1016\/j.bbmt.2019.09.013","article-title":"Dual T cell depletion with anti-Thymocyte globulin and post-transplant cyclophosphamide results in low rates of cytokine release syndrome in peripheral blood Haplo-hematopoietic stem cell transplantation","volume":"25","author":"Salas","year":"2019","journal-title":"Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant"},{"issue":"2","key":"10.1016\/j.blre.2023.101080_bb0675","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1182\/blood-2014-05-552729","article-title":"Current concepts in the diagnosis and management of cytokine release syndrome","volume":"124","author":"Lee","year":"2014","journal-title":"Blood."},{"issue":"4","key":"10.1016\/j.blre.2023.101080_bb0680","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant"},{"key":"10.1016\/j.blre.2023.101080_bb0685","doi-asserted-by":"crossref","DOI":"10.1177\/0963689720965900","article-title":"Post-transplant cyclophosphamide and thymoglobulin, a graft-versus-host disease prophylaxis in matched sibling donor peripheral blood stem cell transplantations","volume":"29","author":"Kunacheewa","year":"2020","journal-title":"Cell Transplant"},{"issue":"14","key":"10.1016\/j.blre.2023.101080_bb0690","doi-asserted-by":"crossref","first-page":"3373","DOI":"10.1080\/10428194.2021.1966781","article-title":"Lower dose of ATG combined with post-transplant cyclophosphamide for HLA matched RIC alloHCT is associated with effective control of GVHD and less viral infections","volume":"62","author":"Salas","year":"2021","journal-title":"Leuk Lymphoma"},{"issue":"3","key":"10.1016\/j.blre.2023.101080_bb0695","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1038\/s41409-017-0053-9","article-title":"Reduction of severe acute graft-versus-host disease using a combination of pre transplant anti-thymocyte globulin and post-transplant cyclophosphamide in matched unrelated donor transplantation","volume":"53","author":"Deotare","year":"2018","journal-title":"Bone Marrow Transplant"},{"issue":"6","key":"10.1016\/j.blre.2023.101080_bb0700","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1111\/ejh.13230","article-title":"Low rates of acute and chronic GVHD with ATG and PTCy in matched and mismatched unrelated donor peripheral blood stem cell transplants","volume":"102","author":"Prem","year":"2019","journal-title":"Eur J Haematol"},{"issue":"4","key":"10.1016\/j.blre.2023.101080_bb0705","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1111\/ejh.13735","article-title":"Anti-thymocyte globulin and post-transplant cyclophosphamide do not abrogate the inferior outcome risk conferred by human leukocyte antigen-a and -B mismatched donors","volume":"108","author":"Novitzky-Basso","year":"2022","journal-title":"Eur J Haematol"},{"issue":"10","key":"10.1016\/j.blre.2023.101080_bb0710","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1038\/s41409-022-01754-y","volume":"57","author":"Zu","year":"2022","journal-title":"Bone Marrow Transplant"},{"issue":"12","key":"10.1016\/j.blre.2023.101080_bb0715","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1038\/s41409-022-01816-1","article-title":"Should anti-thymocyte globulin be added in post-transplant cyclophosphamide based matched unrelated donor peripheral blood stem cell transplantation for acute myeloid leukemia? A study on behalf of the acute leukemia working party of the EBMT","volume":"57","author":"Spyridonidis","year":"2022","journal-title":"Bone Marrow Transplant"},{"issue":"15","key":"10.1016\/j.blre.2023.101080_bb0720","doi-asserted-by":"crossref","first-page":"2881","DOI":"10.1002\/cncr.30540","article-title":"Optimal dose of rabbit thymoglobulin in conditioning regimens for unmanipulated, haploidentical, hematopoietic stem cell transplantation: long-term outcomes of a prospective randomized trial","volume":"123","author":"Chang","year":"2017","journal-title":"Cancer."},{"issue":"24","key":"10.1016\/j.blre.2023.101080_bb0725","doi-asserted-by":"crossref","first-page":"2498","DOI":"10.1016\/j.scib.2021.06.002","article-title":"Optimizing antithymocyte globulin dosing in haploidentical hematopoietic cell transplantation: long-term follow-up of a multicenter, randomized controlled trial","volume":"66","author":"Wang","year":"2021","journal-title":"Sci Bull"},{"issue":"7","key":"10.1016\/j.blre.2023.101080_bb0730","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1007\/s00277-016-2654-6","article-title":"The clinical features of fatal cyclophosphamide-induced cardiotoxicity in a conditioning regimen for allogeneic hematopoietic stem cell transplantation (Allo-HSCT)","volume":"95","author":"Ishida","year":"2016","journal-title":"Ann Hematol"},{"issue":"2","key":"10.1016\/j.blre.2023.101080_bb0735","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.jaccao.2021.02.011","article-title":"Early cardiac toxicity associated with post-transplant cyclophosphamide in allogeneic stem cell transplantation","volume":"3","author":"Dul\u00e9ry","year":"2021","journal-title":"JACC CardioOncology"},{"issue":"2","key":"10.1016\/j.blre.2023.101080_bb0740","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1182\/bloodadvances.2020003005","article-title":"Impaired T- and NK-cell reconstitution after haploidentical HCT with posttransplant cyclophosphamide","volume":"5","author":"Rambaldi","year":"2021","journal-title":"Blood Adv"},{"issue":"3","key":"10.1016\/j.blre.2023.101080_bb0745","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1038\/s41409-020-01065-0","article-title":"Reduced dose of posttransplant cyclophosphamide in HLA-haploidentical peripheral blood stem cell transplantation","volume":"56","author":"Sugita","year":"2021","journal-title":"Bone Marrow Transplant"},{"issue":"4","key":"10.1016\/j.blre.2023.101080_bb0750","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1038\/s41409-022-01908-y","article-title":"Reduced post-transplant cyclophosphamide doses in haploidentical hematopoietic cell transplantation for elderly patients with hematological malignancies","volume":"58","author":"Dul\u00e9ry","year":"2023","journal-title":"Bone Marrow Transplant"}],"container-title":["Blood Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X23000413?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X23000413?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T20:29:13Z","timestamp":1759436953000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0268960X23000413"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":150,"alternative-id":["S0268960X23000413"],"URL":"https:\/\/doi.org\/10.1016\/j.blre.2023.101080","relation":{},"ISSN":["0268-960X"],"issn-type":[{"value":"0268-960X","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Combining post-transplant cyclophosphamide with antithymocyte globulin for graft-versus-host disease prophylaxis in hematological malignancies","name":"articletitle","label":"Article Title"},{"value":"Blood Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.blre.2023.101080","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"101080"}}